Therapeutics Against Infectious Diseases Phase 1

The National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) established this Master IDIQ on December 15, 2014 to support Phase I clinical trials moving promising infectious disease therapeutics into the clinical pipeline. The vehicle is no longer active—the last date to place orders was December 14, 2021, nearly four and a half years ago, and all task orders have been fully obligated against the $90 million shared ceiling.

The 36 task orders awarded through the vehicle's life concentrated on clinical trial execution, administrative operations support, and protocol development for therapeutic candidates across infectious disease areas including malaria. Task orders ranged from small administrative and closeout actions under $200,000 to larger study execution awards exceeding $5 million. The most recent orders, placed in December 2021, included one study award of $5.2 million with completion through December 2024 and several smaller administrative and Phase I base funding orders.

Competition was narrow and remained stable throughout the vehicle's tenure. Three primes captured all 36 orders: Dynport Vaccine Company LLC held 13 orders worth $15.9 million combined potential value, Duke University held 12 orders worth $5.2 million, and Icon Government and Public Health Solutions, Inc. held 11 orders worth $2.8 million. No set-asides were used across any task orders. Ordering momentum declined over the final five years, dropping from 8 orders in 2017 to 3 in 2020 before recovering slightly to 5 in 2021 as the vehicle reached its close date.

All 36 task orders funded a single customer: NIAID. The combined task-order potential value of $23.9 million represents full utilization of available funding under the vehicle. Most task orders used cost-plus-fixed-fee pricing, with a smaller subset priced as cost-no-fee arrangements. This vehicle is closed to new ordering and unsuitable for pursuit.

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), has awarded a Master IDIQ to support a Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases in order to move promising therapeutic candidates into the clinical pipeline. Such studies are often on the critical path for product development.